Dogwood Therapeutics Achieves Nasdaq Compliance
Dogwood Therapeutics, Inc. (Nasdaq: DWTX), a biopharmaceutical company in the development stage, is dedicated to creating innovative medicines targeting pain and fatigue-related conditions. Recently, the company announced that they have received verification from Nasdaq confirming their compliance with the Nasdaq Listing Rule 5550(b)(1), a requirement that mandates a minimum stockholders’ equity of $2.5 million.
Leadership Reactions and Company Strategem
Greg Duncan, the Chairman and CEO of DWTX, expressed satisfaction with the company’s successful efforts to comply with the equity requirement. He noted that the strategy implemented to regain compliance is being effectively executed. As of the end of the first quarter, the company boasts a robust cash position of $17.5 million. Furthermore, they are actively dosing participants in their Halneuron Phase 2b trial aimed at chemotherapy-induced neuropathic pain, anticipating interim data analysis to take place later this year.
Previous Notifications and Compliance Plan
On November 15 of the previous year, Dogwood Therapeutics received a notice informing them that their stockholders’ equity had dipped below the necessary $2.5 million threshold. In response, the company quickly formulated and submitted a compliance plan to Nasdaq on December 27, around six weeks after receiving the notice. This proactive approach led to Nasdaq granting them until May 14 of this year to restore compliance with their Listing Rule. On April 8, Nasdaq confirmed that based on the company's Form 8-K submitted on April 3, they have met the compliance standards.
Company Overview and Development Initiatives
Dogwood Therapeutics focuses on innovative therapies to address pain and related disorders. Their research pipeline is diverse, featuring two distinct mechanistic platforms. One of their key areas is a non-opioid analgesic program led by Halneuron, a proprietary molecule specifically designed to modulate voltage-gated sodium channels, a target known for its efficacy in pain management. Clinical trials have shown that Halneuron effectively reduces pain in patients dealing with general cancer-related discomfort and chronic chemotherapy-induced neuropathic pain (CINP). Anticipations are high for the interim data from the ongoing Phase 2 CINP study, projected to be released later this year.
Antiviral Program Overview
In addition to their analgesic efforts, Dogwood has also developed an antiviral program featuring two novel products, IMC-1 and IMC-2. These proprietary formulations combine anti-herpes antivirals with the anti-inflammatory medication celecoxib. These dual-action approaches are aimed at treating conditions linked to the reactivation of dormant herpes viruses, including fibromyalgia and the lingering effects of Long-COVID. Notably, IMC-1 is set to advance into Phase 3 clinical trials for fibromyalgia, while IMC-2 has been successfully carried through both active control and placebo-controlled clinical trials for its role in alleviating fatigue associated with Long-COVID. The FDA has agreed to recognize fatigue reduction as the primary endpoint for continued studies on IMC-2, which is being prepared for Phase 2b analysis.
Contact Information for Investors
For further inquiries, stakeholders can reach Dogwood Therapeutics' investor relations team at:
CORE IR
(516) 222-2560
IR@dwtx.com
Frequently Asked Questions
What is Dogwood Therapeutics focused on developing?
Dogwood Therapeutics concentrates on creating new medicines for pain and fatigue-related disorders.
What recent confirmation did Dogwood Therapeutics receive from Nasdaq?
They received confirmation of compliance with Nasdaq Listing Rule 5550(b)(1), requiring a minimum stockholders' equity of $2.5 million.
What is Halneuron?
Halneuron is a lead development candidate by Dogwood Therapeutics, aimed at reducing pain through modulation of sodium channels.
What antiviral products are in Dogwood's pipeline?
Dogwood is developing two antiviral products, IMC-1 and IMC-2, which focus on treating illnesses related to herpes viruses.
Who can investors contact for more information?
Investors can contact CORE IR at (516) 222-2560 or via email at IR@dwtx.com.
